Beijing Airdoc Technology Co., Ltd.
北京鷹瞳科技發展股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2251)

INSIDE INFORMATION
COMPLETION OF AIRDOC-AIFUNDUS (2.0) CLINICAL TRIAL WITH OUTSTANDING RESULTS

This announcement is made by Beijing Airdoc Technology Co., Ltd. (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company recently completed the clinical trial of its core product Airdoc-AIFUNDUS (2.0), an AI-based auxiliary diagnosis Software as a Medical Device ("**SaMD**") designed for multiple indications. With the coverage of indications expanded from diabetic retinopathy covered by its previous version to hypertensive retinopathy, retinal vein occlusion and age-related macular degeneration ("**AMD**"), Airdoc-AIFUNDUS (2.0) presented an outstanding sensitivity and specificity for these four diseases, further improving from the sensitivity of 91.75% and specificity of 93.10% demonstrated by Airdoc-AIFUNDUS (1.0) which was approved by the National Medical Products Administration of China (the "**NMPA**"). This serves as a strong testament to the Company's competitive edges in technology as it is able to continue optimizing its algorithms for better performance. Having such industry-leading clinical trial results, the Company is now preparing to apply to the NMPA for an updated Class III medical device certificate for the new indications. Airdoc-AIFUNDUS (2.0) is the first AI-based auxiliary diagnosis SaMD for expanded multiple indications in China that has completed the clinical trial and thus is ready for the application of the NMPA registration, allowing the Company to not only increase its application in more clinical departments going forward but also gain a head start among competition.

As the population is ageing in China, the prevalence of chronic diseases and eye diseases continues to rise. It has created a massive yet unmet clinical demand for effective screenings of these diseases due to the imbalance between large patient populations and limited medical resources. The Company's Airdoc-AIFUNDUS (2.0) targets to cover a large patient base while there is only a very small number of experienced retinal doctors in China. Hypertensive retinopathy is a possible complication of having hypertension and considered to be one of the most important factors to detect and monitor severe hypertension. As one of the most common chronic diseases in China, hypertension has been suffered by 245 million Chinese while the control rate is only less than 20%, according to the *Annual Report on Cardiovascular Health and Diseases in China (2021)*. Retinal vein occlusion, also known as "eye stroke", is a common retinal vascular disease with central retinal vein occlusion often occurring concurrently with cerebral ischemic stroke. Cerebral stroke (commonly known as stroke) is the leading death cause in China, according to a research paper jointly published on the *Lancet* by the Chinese Center for Disease Control and Prevention and the University of Washington's Institute for Health Metrics and Evaluation in 2019. In addition, AMD is one of the major causes of visual impairment among people over the age of 50. With hypertensive retinopathy, retinal vein occlusion and AMD being included by Airdoc-AIFUNDUS (2.0), the product, once approved, can not only assist physicians in the departments of cardiovascular, neurology and ophthalmology with detection and diagnoses of relevant diseases, but also facilitate continuous monitoring of the clinical effects of relevant drugs, both of which are expected to significantly increase the product's potential penetration in hospitals as well as its sales opportunities and market size.

In addition, as cardiovascular diseases are creating an increasingly heavy burden for China's public health system, Airdoc-AIFUNDUS (2.0), once approved, can also enable the Company to better play its part in helping address severe public health issues in China, especially when it is being utilized in primary healthcare institutions where there often lack of high-quality medical resources. Furthermore, the algorithms developed for Airdoc-AIFUNDUS (2.0) can also lay a solid foundation for the large-scale screenings of relevant diseases as well as contribute to people's personal health management and health management services provided by insurance companies and health management institutions. This also represents a key step forward towards the Company's goal of inclusive healthcare and mission to make high-quality healthcare accessible and affordable to everyone.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The Company cannot guarantee that it will ultimately commercialize its Airdoc-AIFUNDUS (2.0). Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, September 14, 2022

As of the date of this announcement, the Board comprises Mr. ZHANG Dalei, Mr. GAO Fei, Dr. CHEN Yuzhong and Mr. CHEN Hailong as executive Directors; Mr. CHEN Xin and Ms. WANG Mi as non-executive Directors; and Mr. NG Kong Ping Albert, Mr. WU Yangfeng and Mr. HUANG Yanlin as independent non-executive Directors.